Sonoma Pharmaceuticals (SNOA) Gross Profit (2010 - 2026)

Sonoma Pharmaceuticals has reported Gross Profit for 17 years, with the latest figure at $2.6 million in Q2 2026.

• On a quarterly basis, Gross Profit rose 76.02% year-over-year to $2.6 million in Q2 2026; TTM through Jun 2026 was $8.5 million, a 51.66% increase from a year earlier, with the FY2026 full-year figure at $7.4 million, up 35.68% from the prior year.
• Gross Profit was $2.6 million for Q2 2026 at Sonoma Pharmaceuticals, up from $2.2 million in the prior quarter.
• The five-year high for Gross Profit was $2.6 million in Q2 2026, with the low at $96000.0 in Q1 2022.
• Average Gross Profit over 5 years is $1.4 million, with a median of $1.4 million recorded in 2023.
• The largest YoY upside for Gross Profit was 800.0% in 2023 against a maximum downside of 35.55% in 2023.
• Over 5 years, Gross Profit stood at $831000.0 in 2022, then surged by 75.69% to $1.5 million in 2023, then decreased by 13.01% to $1.3 million in 2024, then rose by 29.92% to $1.6 million in 2025, then surged by 56.18% to $2.6 million in 2026.
• The last three Gross Profit figures came in at $2.6 million (Q2 2026), $2.2 million (Q1 2026), and $1.6 million (Q4 2025), per Business Quant data.